EdgeMarket › What Ikarian Capital, Llc reported owning
What Ikarian Capital, Llc reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
1.2BPositions
161Quarter
2026-03-31Shown below
50largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| unmapped CUSIP 880881107 | 76.8M | 6.2% | 1.5M | — | — |
| KOD Kodiak Sciences Inc. | 48.3M | 3.9% | 1.3M | 38.33 | +303.5% |
| ALMS ALUMIS INC. | 26.7M | 2.2% | 1.2M | 24.17 | +448.1% |
| PCVX Vaxcyte, Inc. | 24.9M | 2.0% | 428.7K | 62.62 | +100.3% |
| PRAX Praxis Precision Medicines, Inc. | 23.1M | 1.9% | 71.6K | 375.94 | +730.8% |
| HROW HARROW, INC. | 19.1M | 1.6% | 543.0K | 40.95 | +7.1% |
| RLMD RELMADA THERAPEUTICS, INC. | 18.7M | 1.5% | 2.7M | 4.63 | +655.9% |
| CYTK CYTOKINETICS INC | 18.7M | 1.5% | 283.6K | 76.84 | +105.9% |
| TENX TENAX THERAPEUTICS, INC. | 16.3M | 1.3% | 1.0M | 1.75 | -70.7% |
| CAPR CAPRICOR THERAPEUTICS, INC. | 16.1M | 1.3% | 528.0K | 6.29 | -12.3% |
| RVMD Revolution Medicines, Inc. | 15.9M | 1.3% | 163.1K | 209.46 | +479.3% |
| CLDX Celldex Therapeutics, Inc. | 14.6M | 1.2% | 461.2K | 40.38 | +93.3% |
| PHVS Pharvaris N.V. | 13.8M | 1.1% | 486.9K | 36.27 | +57.7% |
| CNTB Connect Biopharma Holdings Ltd | 13.1M | 1.1% | 5.4M | 2.36 | +41.3% |
| DRUG BRIGHT MINDS BIOSCIENCES INC. | 12.2M | 1.0% | 166.6K | 77.42 | +80.0% |
| BBIO BridgeBio Pharma, Inc. | 11.9M | 1.0% | 160.1K | 81.50 | +66.7% |
| ORKA Oruka Therapeutics, Inc. | 11.9M | 1.0% | 242.0K | 107.96 | +649.7% |
| ANRO Alto Neuroscience, Inc. | 11.6M | 0.9% | 515.0K | 34.28 | +899.4% |
| unmapped CUSIP 834203309 | 11.5M | 0.9% | 344.1K | — | — |
| MAZE Maze Therapeutics, Inc. | 11.3M | 0.9% | 379.0K | 29.43 | +118.3% |
| ANIP ANI PHARMACEUTICALS INC | 11.3M | 0.9% | 147.1K | 75.35 | -16.9% |
| CTNM Contineum Therapeutics, Inc. | 10.6M | 0.9% | 807.9K | 17.19 | +93.8% |
| RARE Ultragenyx Pharmaceutical Inc. | 10.1M | 0.8% | 482.6K | 25.83 | -12.0% |
| IONS IONIS PHARMACEUTICALS INC | 9.5M | 0.8% | 127.0K | 59.74 | +39.5% |
| OLMA Olema Pharmaceuticals, Inc. | 8.9M | 0.7% | 598.3K | 10.69 | +96.1% |
| EPRX EUPRAXIA PHARMACEUTICALS INC. | 8.8M | 0.7% | 1.2M | 6.73 | +27.1% |
| DMRA Damora Therapeutics, Inc. | 8.7M | 0.7% | 335.7K | 30.82 | +811.9% |
| PVLA PALVELLA THERAPEUTICS, INC. | 8.1M | 0.7% | 64.6K | 142.04 | +181.6% |
| FULC Fulcrum Therapeutics, Inc. | 8.0M | 0.7% | 1.0M | 3.83 | -41.7% |
| VERA Vera Therapeutics, Inc. | 8.0M | 0.7% | 200.0K | 32.27 | +46.0% |
| SPRB SPRUCE BIOSCIENCES, INC. | 7.9M | 0.6% | 121.4K | 51.58 | +65523.4% |
| IVA Inventiva S.A. | 7.8M | 0.6% | 1.4M | 4.68 | +2.2% |
| JBIO Jade Biosciences, Inc. | 7.2M | 0.6% | 512.3K | 21.34 | +211.5% |
| OCGN Ocugen, Inc. | 7.2M | 0.6% | 4.0M | 1.39 | +37.6% |
| ZURA Zura Bio Ltd | 7.1M | 0.6% | 1.2M | 5.85 | +234.3% |
| OVID Ovid Therapeutics Inc. | 6.4M | 0.5% | 2.9M | 2.80 | +194.7% |
| ABVX Abivax S.A. | 6.2M | 0.5% | 57.6K | 114.95 | +59.9% |
| LLY ELI LILLY & Co | 6.0M | 0.5% | 6.5K | 1,255.40 | +78.0% |
| ACOG Alpha Cognition Inc. | 5.8M | 0.5% | 1.1M | 9.75 | +22.0% |
| PTHS Pelthos Therapeutics Inc. | 5.4M | 0.4% | 256.6K | 25.51 | +19.1% |
| SRZN Surrozen, Inc./DE | 5.0M | 0.4% | 173.1K | 23.99 | +108.6% |
| TECX Tectonic Therapeutic, Inc. | 4.9M | 0.4% | 157.5K | 37.63 | +56.3% |
| ALEC Alector, Inc. | 4.5M | 0.4% | 2.1M | 2.36 | +7.3% |
| LEGN Legend Biotech Corp | 4.1M | 0.3% | 226.9K | 21.82 | -38.8% |
| KPTI Karyopharm Therapeutics Inc. | 4.1M | 0.3% | 733.4K | 1.96 | -69.8% |
| LPCN Lipocine Inc. | 4.1M | 0.3% | 508.6K | 2.09 | -31.2% |
| DCTH DELCATH SYSTEMS, INC. | 4.0M | 0.3% | 431.3K | 17.14 | +65.9% |
| ARVN ARVINAS, INC. | 3.8M | 0.3% | 358.3K | 9.37 | +31.9% |
| CMPS COMPASS Pathways plc | 3.7M | 0.3% | 675.0K | 13.33 | +226.7% |
| CRDL Cardiol Therapeutics Inc. | 3.7M | 0.3% | 2.7M | 1.86 | +60.3% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →